<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140540</url>
  </required_header>
  <id_info>
    <org_study_id>RGCI ID:500/AN/ANK-02</org_study_id>
    <nct_id>NCT03140540</nct_id>
  </id_info>
  <brief_title>TEE as a Guide for Fluid Optimization in Major Abdominal Oncosurgery</brief_title>
  <acronym>VTI SVV</acronym>
  <official_title>Transesophageal Echocardiography as a Guide for Fluid Optimization in Major Abdominal Oncosurgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajiv Gandhi Cancer Institute &amp; Research Center, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajiv Gandhi Cancer Institute &amp; Research Center, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transesophageal echocardiography (TEE) as guide for tailoring perioperative fluid therapy to&#xD;
      achieve individualized hemodynamic endpoint, target hemodynamic goals of stroke volume index&#xD;
      (SVI) greater than 35 mL/m2 and cardiac index greater than 2.5 L/min/m2 and tissue oxygen&#xD;
      delivery.&#xD;
&#xD;
      Lactate levels as a surrogate indicator of organ perfusion as measured by arterial blood gas&#xD;
      analysis intraoperatively, after 12 hours and 48 hrs postoperatively&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TEE as guide for tailoring perioperative fluid therapy to achieve target hemodynamic goals of&#xD;
      stroke volume index (SVI) greater than 35 mL/m2 and cardiac index greater than 2.5 L/min/m2&#xD;
      and tissue oxygen delivery.&#xD;
&#xD;
      GDT (goal directed therapy): continuous infusion of crystalloids 2 mL/kg/h.&#xD;
&#xD;
      If (velocity time integral) VTI &lt;20, 250 mL colloid bolus administered. Dose repeated every&#xD;
      10 min until goal of VTI &gt;20 met. Norepinephrine titrated to maintain MAP(mean arterial&#xD;
      pressure) &gt; 65 mm Hg. Blood transfused for haemoglobin &lt;8 g Lactate levels as a surrogate&#xD;
      indicator of organ perfusion as measured by arterial blood gas analysis at time of incision&#xD;
      intraoperatively and after 12 hours and 48 hrs. The incidence of postoperative complications,&#xD;
      morbidity, mortality, duration of mechanical ventilation and ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TEE as guide for tailoring perioperative fluid therapy to achieve individualized hemodynamic endpoint , target hemodynamic goals of stroke volume index (SVI) greater than 35 mL/m2 and cardiac index greater than 2.5 L/min/m2 and tissue oxygen delivery. Lactate levels as a surrogate indicator of organ perfusion as measured by arterial blood gas analysis intraoperatively , after 12 hours and 48 hrs postoperatively.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>The intensivist taking care of the patient postoperatively not aware of the intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>48 hours</time_frame>
    <description>The incidence of postoperative complications in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraoperative fluid</measure>
    <time_frame>intraoperative period (hours)</time_frame>
    <description>Amount of intraoperative fluid in litres to be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median icu stay</measure>
    <time_frame>1 week</time_frame>
    <description>duration of icu stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fluid Therapy</condition>
  <arm_group>
    <arm_group_label>Group A (stroke volume variation) guided fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stroke volume variation guided intraoperative intravenous fluid will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B(Study group) TEE guided fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transesophageal echocardiography will be used to guide the fluid therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TEE guided fluid therapy will be administered</intervention_name>
    <description>Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta &lt;20 ,200ml colloid bolus to be administered.</description>
    <arm_group_label>Group B(Study group) TEE guided fluid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stroke volume variation guided intravenous fluid.</intervention_name>
    <description>Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV &gt;10, 200 ml of colloid bolus to be given</description>
    <arm_group_label>Group A (stroke volume variation) guided fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA 1, 2 and 3&#xD;
&#xD;
          -  Undergoing major abdominal oncosurgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication for TEE probe insertion as oesophageal varices , oesophageal and&#xD;
             gastric carcinoma , severe left ventricular hypertrophy , coagulopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rajiv Gandhi Cancer Institute</name>
      <address>
        <city>Delhi</city>
        <zip>110085</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Guarracino F. [The role of transesophageal echocardiography in intraoperative hemodynamic monitoring]. Minerva Anestesiol. 2001 Apr;67(4):320-4. Italian.</citation>
    <PMID>11376533</PMID>
  </results_reference>
  <results_reference>
    <citation>Trinooson CD, Gold ME. Impact of goal-directed perioperative fluid management in high-risk surgical procedures: a literature review. AANA J. 2013 Oct;81(5):357-68. Review.</citation>
    <PMID>24354071</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rajiv Gandhi Cancer Institute &amp; Research Center, India</investigator_affiliation>
    <investigator_full_name>Dr soumi pathak</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Fluid management</keyword>
  <keyword>goal-directed therapy</keyword>
  <keyword>transesophageal echocardiography</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

